Skip to main content
Clinical Trials/NCT02169700
NCT02169700CompletedNot Applicable

Ischemic Compression After Dry Needling of a Latent Myofascial Trigger Point Reduces Post-needling Soreness Intensity and Duration.

Universidad Rey Juan Carlos1 site in 1 country90 target enrollmentStarted: December 1, 2013Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
90
Locations
1
Primary Endpoint
Visual analog scale (VAS)

Study Overview

Brief Summary

Myofascial trigger points (MTrPs) are identified through physical examination as hypersensitive spots within taut bands of skeletal muscle, painful on compression, triggering characteristic referred pain and generating motor dysfunction as well as autonomic phenomena. Different dry needling procedures have been described in the treatment of MTrPs. Needling therapies which consist in partially inserting and withdrawing the needle from the trigger point site in order to elicit local twitch responses are associated with higher effectiveness in releasing MTrPs. Deep dry needling has obtained a grade A recommendation compared to sham, for immediate reduction of pain in patients with upper-quadrant myofascial pain syndrome. Nevertheless, trigger point dry needling are frequently associated to a post-needling soreness. The application of ischemic compression (IC) after trigger point injection in the upper trapezius muscle has shown higher reduction of pain and disability in myofascial pain patients, compared with trigger point injection alone. To the authors' knowledge, no previous studies have evaluated the effectiveness of IC or any manual therapy methods for the treatment of post-needling soreness. The aims of this study were: (a) to evaluate the effectiveness of IC on reducing post-needling soreness after dry needling of one latent MTrP in the upper trapezius muscle, and (b) to investigate the effect dry needling combined with IC, compared to dry needling alone and dry needling combined with placebo IC will have on cervical range of motion (c) to determine whether psychological factors are predictive of postneedling pain and (d) to analyze if the relationships between psychological variables and postneedling pain varied as a function of postneedling soreness treatment

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 39 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Subjects were included if they presented at least one latent MTrP in the upper trapezius muscle

Exclusion Criteria

  • •Presence of coagulation disorders
  • •Neck or facial pain
  • •Previous application of a dry needling technique
  • •MTrP therapy in head or neck within the previous 3 months
  • •Fibromyalgia
  • •An insurmountable fear of needles as a reason of refusing the treatment
  • •History of surgery in the head or neck area

Arms & Interventions

Ischemic compression. Dry Needling

Experimental

Ischemic compression was carried out after dry needling.

Intervention: Ischemic compression. Dry Needling (Procedure)

Sham Ischemic compression. Dry Needling

Sham Comparator

Sham Ischemic compression was carried out after dry needling.

Intervention: Ischemic compression. Dry Needling (Procedure)

Control group

No Intervention

No intervention. Control group

Outcomes

Primary Outcomes

Visual analog scale (VAS)

Time Frame: From Baseline in pain intensity at during needling and at 72 hours

VAS. Despite being a subjective evaluation, it has been documented in previous studies its reliability and validity and its sensitivity to the clinical changes. For this reason, this scale has been used in numerous clinical trials. The patient places a vertical mark on a flat horizontal line of 10 cm. One extreme is 0 (no pain) and the other extreme is 10 (maximum pain) and it must be a difference of 2 points in the evaluation range to produce minimal improvement which is clinically significant

Secondary Outcomes

  • Cervical Range of Motion (CROM)(CROM measurements were taken before needling, after the intervention, and at 24 and 72 hours post-treatment.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Josue Fernandez Carnero

PhD

Universidad Rey Juan Carlos

Study Sites (1)

Loading locations...

Similar Trials